DAVIS J MORTON Form SC 13G August 15, 2002

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

washington, D.C. 20349
SCHEDULE 13G
Under the Securities Exchange Act of 1934  (Amendment No)*
Indevus Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, \$.001 par value
(Title of Class of Securities)
454072109
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[XX] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 1 of 6 pages
CUSIP No. 454072109 13G Page 2 of 6 Pages

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

J. Morton	Davis	
2 CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP*  (a) [ ] (b) [ ]	
3 SEC USE ON	LY	
4 CITIZENSHI	P OR PLACE OF ORGANIZATION	
New York		
SHARES BENEFICIALLY	5 SOLE VOTING POWER 3,359,393	
	6 SHARED VOTING POWER 0	
	7 SOLE DISPOSITIVE POWER 3,359,393	
	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,359,393	
10 CHECK BOX	IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	
11 PERCENT OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	7.2%	
12 TYPE OF RE	PORTING PERSON*	
PN		
	*SEE INSTRUCTIONS BEFORE FILLING OUT	

13G

CUSIP No. 454072109

Page 3 of 6 Pages

1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
D.H. Blair Investment Banking Corp.			
2 CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP*  (a) [ ]  (b) [ ]		
3 SEC USE ON	LY		
4 CITIZENSHI	P OR PLACE OF ORGANIZATION		
Delaware			
NUMBER OF SHARES BENEFICIALLY	5 SOLE VOTING POWER 3,250,637		
	6 SHARED VOTING POWER 0		
	7 SOLE DISPOSITIVE POWER 3,250,637		
	8 SHARED DISPOSITIVE POWER		
	0		
9 AGGREGATE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,250,637		
10 CHECK BOX	IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
11 PERCENT OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	7%		
12 TYPE OF RE			
	co.		
	*CFF INCTDICTIONS DEFODE FILLING OUT		

Page 4 of 6 Pages

#### Item 1.

- (a) Name of Issuer: Indevus Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices: One Ledgemont Center 99 Hayden Avenue Lexington, MA 02421

#### Item 2.

- (a) Name of Person Filing:
  - J. Morton Davis and D.H. Blair Investment Banking Corp.
    ("Blair Investment") (together, the "Reporting Parties").
- (b) Address of Principal Business Office or, if None, Residence:

The Reporting Parties' business address is 44 Wall Street, New York, NY 10005.

(c) Citizen:

Mr. Davis is a United States citizen. Blair Investment is incorporated in the State of Delaware.

- (d) Title of Class of Securities: Common Stock, \$.001 par value ("shares").
- (e) CUSIP#: 454072109
- Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
  - (a) [X] Broker or Dealer registered under Section 15 of the Act
  - (b) [ ] Bank as defined in section 3(a)(6) of the Act
  - (c) [ ] Insurance Company as defined in section 3(a)(19) of the Act
  - (d) [] Investment Company registered under section 8 of the Investment Company Act of 1940

  - (f) [ ] An employee benefit Plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F)
  - (g) [ ] A parent holding Company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
  - (h) [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act
  - (i) [ ] A church plan that is excluded from definition of an

investment company under section 3(c)(14) of the Investment Company Act of 1940.

Page 5 of 6 Pages

#### Item 4. Ownership:

(a) (b) As of August 7, 2002, Mr. Davis may be deemed to beneficially own 3,359,393 shares or 7.2% of the Issuer's shares issued and outstanding as follows: (i) 50,156 shares owned directly by Mr. Davis, (ii) 3,250,637 shares owned directly by Blair Investment, and (iii) 58,600 shares owned directly by Rosalind Davidowitz (1).

As of August 7, 2002, Blair Investment may be deemed to beneficially own 3,250,637 shares or 7% of the Issuer's shares issued and outstanding as indicated in (ii) above.

- (c) Mr. Davis has sole power to vote or to direct the vote, to dispose or to direct the disposition of those shares owned by Blair Investment. Rosalind Davidowitz has sole voting and dispositive power over those shares owned directly by her.
- Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

<sup>(1)</sup> Rosalind Davidowitz is Mr. Davis' wife. Filing of this statement shall not be deemed an admission by J. Morton Davis that he beneficially owns the securities attributed to Rosalind Davidowitz for any purpose. J. Morton Davis expressly disclaims beneficial ownership of all securities held by Rosalind

Davidowitz for any purpose.

Page 6 of 6 Pages

Item 10. Certification: By signing below we certify that to the best of our knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as participant in any transaction having such purpose of effect.

#### SIGNATURES

After reasonable inquiry and to the best knowledge and belief of the Reporting Persons, each such person or entity certifies that the information set forth in this statement is true, complete and correct.

Dated: August 8, 2002
New York, New York

D.H. Blair Investment Banking Corp.